Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Study results suggest that a higher hemoglobin threshold may lead to more transfusions for preterm infants with anemia but without improving outcomes.
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
A new study explores disruption of tryptophan metabolism, manifesting as dysregulation of serotonin metabolism, in patients with Fanconi anemia.
In a short-term trial involving hemodialysis patients, ziltivekimab significantly improved erythropoietin resistance index.
The Agency announced that additional clarification of clinical data was needed prior to completing the review.
Among patients with sickle cell disease, inhibition of BCL11A via gene knockdown is an effect target to induce fetal hemoglobin.
The comparative study aimed to analyze AEs as well as estimate the associated medical costs for 4 IV iron preparations.
Preliminary results suggest that CRISPR-Cas9 editing of BCL11A may benefit patients with sickle cell disease and β-thalassemia by potentially eliminating vaso-occlusive episodes or the need for transfusion.